Fully Integrated Platform

Ascletis is an innovative R&D driven biotech with two commercial products and listed on Hong Kong Stock Exchange (Ascletis, 1672.HK). Ascletis’ mission is to address unmet medical needs in three therapeutic areas: viral, cancer and fatty liver diseases. Led by a management team with deep expertise and a proven track record, Ascletis has developed a fully integrated platform covering the entire value chain from discovery and development to manufacturing and commercialization.

Antibody-based Immunotherapy

ASC22,PD-L1 antibody for HBV, first-in-class, subcutaneous, room temperature stable,phase 2 ready.

First/Best-in-Class Small Molecules

ASC40, first-in-class FASN inhibitor for NASH, phase 2. ASC09, best-in-class HIV protease inhibitor with unprecedented genetic barrier, phase 2.


ASC06, first systematically delivered, dual-targeting siRNA for liver cancer, phase 1.

Imagine what you could do at Ascletis

Our greatest assets are our employees. Ascletis is an equal opportunity employer and focused on providing a positive work environment where courageous innovation is encouraged and expected.

Our mission is to become a world-class biotechnology company addressing unmet medical needs in three therapeutic areas: anti-viral, cancer and fatty liver disease, for the patients in China and worldwide. Our highly talented team of researchers and professionals who passionately share in this common mission.

We offer competitive salaries and benefits that reward employees for their contribution to the company. If you’re interested in learning more about what we have to offer, please email your CV to [email protected] We will look to match any current and upcoming openings to your area of expertise.

nba比分 足彩比分直播500 今日足球比赛比分 优酷王黄色片 nba比分数据 3d断组预测牛彩网 于海宾今天3d预测 日本av女优快播中文字幕 西安按摩女上门服务 36选7 3d开奖结果查询果 澳门即时赔率加强板 安徽25选5 广西快乐十分彩走势图 开拓者vs马刺 什么是av女优是真做爱吗 北京pk10 3d开机号试机号开 日本av女优希崎谢西嘉秀制服